Department of Ophthalmology, University Hospital Düsseldorf, Düsseldorf, Germany.
Graefes Arch Clin Exp Ophthalmol. 2010 Aug;248(8):1187-92. doi: 10.1007/s00417-010-1379-9. Epub 2010 May 2.
To evaluate the efficacy of suppressing a recurrence of Toxoplasma retinochoroiditis after treatment with atovaquone.
Retrospective, nonrandomized, clinical trial. Forty-one immunocompetent patients were treated for Toxoplasma retinochoroiditis with atovaquone between 1999 and 2006. The diagnosis was based on clinical signs alone. Atovaquone was given 750 mg two to three times daily together with oral steroids. Lesion location, time interval until recurrence, visual function, and adverse events were recorded.
Forty-two eyes of 41 patients were treated with atovaquone for Toxoplasma retinochoroiditis. Side-effects were usually mild and only one patient stopped therapy with atovaquone because of nausea. Reactivation of retinochoroiditis occurred in 18 patients (44%) during a time interval of 3-70 months.
The therapy of Toxoplasma retinochoroiditis with atovaquone is well tolerated. Our data suggests that therapy with atovaquone has the potential to prolong the time to recurrence of Toxoplasma retinochoroiditis. A prospective randomized comparative long-term clinical trial would be necessary to confirm our data.
评估阿托伐醌抑制弓形虫视网膜炎复发的疗效。
回顾性、非随机临床试验。1999 年至 2006 年间，41 例免疫功能正常的弓形虫视网膜炎患者接受阿托伐醌治疗。诊断仅基于临床体征。阿托伐醌每天 2 至 3 次，每次 750mg，同时口服皮质类固醇。记录病变位置、复发时间间隔、视力功能和不良反应。
41 例患者的 42 只眼接受阿托伐醌治疗弓形虫视网膜炎。副作用通常较轻，只有 1 例患者因恶心而停止阿托伐醌治疗。18 例（44%）患者在 3-70 个月的时间间隔内发生视网膜炎再激活。
阿托伐醌治疗弓形虫视网膜炎耐受性良好。我们的数据表明，阿托伐醌治疗可能具有延长弓形虫视网膜炎复发时间的潜力。需要进行前瞻性随机对照长期临床试验来证实我们的数据。
